AN2 Therapeutics (NASDAQ: ANTX) launches new $80M at-the-market stock sale
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
AN2 Therapeutics, Inc. entered an Open Market Sale Agreement with Jefferies that allows it to issue and sell, from time to time, up to $80 million of its common stock through at-the-market offerings under a Form S-3 shelf registration.
Jefferies will act as sales agent and receive a commission of up to 3.0% of gross proceeds. On the same date, AN2 terminated its prior TD Cowen at-the-market program, under which it had already sold 2,502,000 shares for aggregate proceeds of $20,016,251.
Positive
- None.
Negative
- None.
Insights
AN2 adds a new $80M ATM facility while closing an older, smaller program.
AN2 Therapeutics established a new Open Market Sale Agreement with Jefferies, enabling at-the-market issuances of up to $80 million in common stock under an effective Form S-3 shelf. Jefferies will receive a commission of up to 3.0% of gross proceeds.
The company simultaneously terminated its prior TD Cowen at-the-market program after selling 2,502,000 shares for aggregate proceeds of $20,016,251. This shift consolidates its equity issuance channel with a single agent, while preserving flexibility to raise equity as needed over time.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
ATM capacity: $80 million
Sales agent commission: 3.0% of gross proceeds
Shares sold under prior ATM: 2,502,000 shares
+1 more
4 metrics
ATM capacity
$80 million
Maximum aggregate offering amount under new Jefferies agreement
Sales agent commission
3.0% of gross proceeds
Commission payable to Jefferies on stock sold
Shares sold under prior ATM
2,502,000 shares
Total common shares sold via TD Cowen program before termination
Proceeds from prior ATM
$20,016,251
Aggregate offering price achieved under TD Cowen agreement
Key Terms
Open Market Sale Agreement SM, at the market offering, Registration Statement on Form S-3, prospectus supplement, +1 more
5 terms
Open Market Sale Agreement SM financial
"Open Market Sale Agreement SM , dated April 9, 2026, by and between the Company and Jefferies."
at the market offering financial
"by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4)"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Registration Statement on Form S-3 regulatory
"Sales of the shares, if any, will be made pursuant to a Registration Statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
prospectus supplement regulatory
"the base prospectus to be filed as part of such registration statement and a prospectus supplement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
indemnification rights legal
"The Company has also agreed to provide Jefferies with customary indemnification rights."
FAQ
What new equity program did AN2 Therapeutics (ANTX) establish with Jefferies?
AN2 Therapeutics entered an Open Market Sale Agreement with Jefferies, allowing it to sell up to $80 million of common stock in at-the-market offerings under a Form S-3 shelf registration, giving the company flexible access to equity capital over time.
How will Jefferies be compensated under AN2 Therapeutics’ new sales agreement?
Jefferies will act as sales agent and receive a commission of up to 3.0% of the gross proceeds from any AN2 Therapeutics common stock sales made under the Open Market Sale Agreement, aligning its compensation directly with executed transaction volume.
What happened to AN2 Therapeutics’ prior TD Cowen at-the-market program?
Effective April 9, 2026, AN2 Therapeutics terminated its prior TD Cowen Open Market Sale Agreement. Before termination, it had sold 2,502,000 shares of common stock, generating an aggregate offering price of $20,016,251 under that earlier at-the-market facility.
Under what regulatory framework will AN2 Therapeutics’ new stock sales occur?
The new sales will occur under a Form S-3 shelf registration, using a base prospectus and a prospectus supplement. Transactions will qualify as an “at the market offering” under Rule 415(a)(4), primarily through the Nasdaq Global Select Market or other existing trading venues.
Where can investors find the full terms of AN2 Therapeutics’ Jefferies agreement?
The complete Open Market Sale Agreement with Jefferies is filed as Exhibit 1.1 to the report. Investors can review that exhibit to see all terms, including mechanics of share sales, commission structure, termination provisions, and customary indemnification arrangements.